Janux Therapeutics, Inc.

Janux Therapeutics, Inc.verified

JANX

Price:

$44.68

Market Cap:

$2.32B

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many can...[Read more]

Industry

Biotechnology

IPO Date

2021-06-11

Stock Exchange

NASDAQ

Ticker

JANX

The PE Ratio as of July 2024 (TTM) for Janux Therapeutics, Inc. (JANX) is -37.23

According to Janux Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -37.23. This represents a change of 152.36% compared to the average of -14.75 of the last 4 quarters.

Janux Therapeutics, Inc. (JANX) Historical PE Ratio (quarterly & annually)

How has JANX PE Ratio performed in the past?

The mean historical PE Ratio of Janux Therapeutics, Inc. over the last ten years is -97.87. The current -37.23 PE Ratio has changed 3.70% with respect to the historical average. Over the past ten years (40 quarters), JANX's PE Ratio was at its highest in in the June 2023 quarter at -7.09. The PE Ratio was at its lowest in in the March 2021 quarter at -109.84.

Quarterly (TTM)
Annual

Average

-97.87

Median

-24.99

Minimum

-247.00

Maximum

-8.10

Janux Therapeutics, Inc. (JANX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Janux Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual PE Ratio = -8.10

Minimum Annual Increase = -87.45%

Minimum Annual PE Ratio = -247.00

Quarterly (TTM)
Annual
YearPE RatioChange
2023-8.10-19.66%
2022-10.09-59.65%
2021-24.99-87.45%
2020-199.15-19.37%

Janux Therapeutics, Inc. (JANX) Average PE Ratio

How has JANX PE Ratio performed in the past?

The current PE Ratio of Janux Therapeutics, Inc. (JANX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-14.39

5-year avg

-97.87

10-year avg

-97.87

Janux Therapeutics, Inc. (JANX) PE Ratio vs. Peers

How is JANX’s PE Ratio compared to its peers?

Janux Therapeutics, Inc.’s PE Ratio is less than Mineralys Therapeutics, Inc. (-6.53), less than Eliem Therapeutics, Inc. (-13.89), less than Anebulo Pharmaceuticals, Inc. (-6.10), less than Rezolute, Inc. (-3.95), less than Keros Therapeutics, Inc. (-8.89), less than Fennec Pharmaceuticals Inc. (62.39), less than Edgewise Therapeutics, Inc. (-17.67), less than Harmony Biosciences Holdings, Inc. (13.21), less than Molecular Partners AG (-3.28), less than MediciNova, Inc. (-7.82), less than Champions Oncology, Inc. (-9.43), less than Cyteir Therapeutics, Inc. (-3.52), less than Aerovate Therapeutics, Inc. (-0.60), less than Adagene Inc. (-3.85), less than Acrivon Therapeutics, Inc. Common Stock (-2.58), less than AN2 Therapeutics, Inc. (-1.26),

Build a custom stock screener for Janux Therapeutics, Inc. (JANX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Janux Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Janux Therapeutics, Inc. (JANX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Janux Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Janux Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Janux Therapeutics, Inc. (JANX)?

What is the highest PE Ratio for Janux Therapeutics, Inc. (JANX)?

What is the 3-year average PE Ratio for Janux Therapeutics, Inc. (JANX)?

What is the 5-year average PE Ratio for Janux Therapeutics, Inc. (JANX)?

How does the current PE Ratio for Janux Therapeutics, Inc. (JANX) compare to its historical average?